640,000 Shares in Silence Therapeutics plc (NASDAQ:SLN) Purchased by Eventide Asset Management LLC

Eventide Asset Management LLC bought a new stake in Silence Therapeutics plc (NASDAQ:SLN - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 640,000 shares of the company's stock, valued at approximately $11,635,000. Eventide Asset Management LLC owned 2.14% of Silence Therapeutics at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Verition Fund Management LLC acquired a new stake in shares of Silence Therapeutics during the 3rd quarter valued at about $207,000. The Manufacturers Life Insurance Company acquired a new position in shares of Silence Therapeutics during the 3rd quarter worth $318,000. Values First Advisors Inc. bought a new position in shares of Silence Therapeutics during the 3rd quarter valued at $56,000. Point72 Asset Management L.P. boosted its holdings in Silence Therapeutics by 1,686.6% in the second quarter. Point72 Asset Management L.P. now owns 146,500 shares of the company's stock worth $2,784,000 after purchasing an additional 138,300 shares in the last quarter. Finally, Quarry LP acquired a new position in Silence Therapeutics during the second quarter worth $114,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on SLN shares. Chardan Capital reaffirmed a "buy" rating and issued a $55.00 price target on shares of Silence Therapeutics in a research report on Thursday, November 14th. HC Wainwright reissued a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, November 15th. Jefferies Financial Group started coverage on Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $40.00 price target on the stock. Morgan Stanley reiterated an "overweight" rating and issued a $49.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Finally, William Blair reaffirmed an "outperform" rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $57.20.

Silence Therapeutics Trading Up 3.3 %

SLN stock traded up $0.25 during trading on Friday, reaching $7.92. 576,445 shares of the stock were exchanged, compared to its average volume of 249,517. Silence Therapeutics plc has a twelve month low of $5.81 and a twelve month high of $27.72. The company has a market capitalization of $237.05 million, a P/E ratio of -5.04 and a beta of 1.30. The stock has a 50 day simple moving average of $16.04 and a 200-day simple moving average of $18.27.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.